Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Unknown 3Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 61CNS 8Gastrointestinal 4Tumor-Agnostic 3Head & Neck 2Breast 1

Conditions

Pancreatic Neoplasms 2Esophageal Neoplasms 2

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × icotinib × Gastrointestinal × Clear all
NCT01855854 2019-07-05

Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Betta Pharmaceuticals Co., Ltd.

Phase 2 Completed
54 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT02375581 2016-03-22

Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer

First People's Hospital of Hangzhou

Phase 2 Unknown
130 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT02024633 2015-07-15

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02278458 2015-05-22

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡